A stock research company believes Medtronic’s Infuse bone graft problems will open up the market to new alternatives. Cockrell Group Research says that revenues for the Infuse bone graft were down 11% due to severe safety issues with the device.
The group cites independent research from Yale University that confirms Medtronic’s Infuse bone graft increases the risks for severe side effects, including excessive bone growth and retrograde ejaculation. The Infuse side effects have hampered Medtronic’s grasp on the spine device market.
Medtronic Infuse bone graft lawsuits have been piling up after allegations that the company illegally promoted the device. Doctors and patients have been seeking alternatives to the Infuse after studies showed the increased risks of severe side effects.